Novavax, Inc (NASDAQ:NVAX) price is hovering higher on current market day and jumping 7.20% above its previous close. A look at today’s price movement shows that the recent level at last check reads $7.22, with intraday deals fluctuating between $7.2902 and $7.79. The company’s 5Y
Novavax, Inc (NASDAQ:NVAX) traded at $6.74 at last check on current trade day and made a downward move of -3.25% on its previous day’s price. Looking at the stock we see that its previous close was $6.97 and the beta (5Y monthly) reads 2.771 with
The trading price of Novavax, Inc (NASDAQ:NVAX) closed higher on Tuesday, July 08, and closing at $7.04, 6.51% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $6.63 and $7.18. The company’s P/E ratio
Novavax, Inc (NASDAQ:NVAX) price is hovering higher on current market day and jumping 0.95% above its previous close. A look at today’s price movement shows that the recent level at last check reads $6.3, with intraday deals fluctuating between $6.23 and $6.41. The company’s 5Y
Novavax, Inc (NASDAQ:NVAX) shares, rose in value, with the stock price up by 0.08% to the previous day’s close as strong demand from buyers drove the stock to $6.30. Actively observing the price movement in the recent trading, the stock is buoying the session at
Novavax, Inc (NASDAQ:NVAX) price on Wednesday, June 11, fall -1.53% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $7.09. A look at the stock’s price movement, the close in the last trading session was $7.20. The PE
Novavax, Inc (NASDAQ:NVAX) price closed higher on Friday, June 06, and jumping 6.58% above its previous close. A look at the daily price movement shows that the last close reads $6.99. The company’s P/E ratio in the trailing 12-month period read 2.81. Taking into account
Shares of US biotech company Novavax at the August 5 aftermarket trading rose 5%, then plunged more than 17% to $204.76 each. The plunge was in response to the upcoming transfer of the application to the United States Food and Drug Administration (FDA) for approval
In the biotechnology industry, companies produce drugs that treat illness and diagnostic technologies. For these products to be approved by the FDA, the process is lengthy and expensive. Food and Drug Administration (FDA). In this case, investors may have to wait years to find out
Stocks Register is a comprehensive online news hub delivering daily updates on various facets of U.S. life, including business, technology, politics, economy, culture, sports, and noteworthy global events.